An observational study in Hyperthermia and Cancer, sponsored by Pirus Ghadjar. Recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2023-08-15.
Sponsored by Pirus Ghadjar · Observational
This monocentric study registry records all cancer patients at the Charité which are treated with hyperthermia to examine the therapeutic use of hyperthermia in cancer patients in the general application and to obtain an accurate risk-benefit balance
After confinement in this database are the patients prospectively in order to complications, disease status and survival status tracked.
Furthermore there is the possibility in the course of this study to an optional take part in translational accompanying research with the aim of prognostic factors for response to hyperthermia treatment.
A total of 1000 patients with various diseases with the indication for hyperthermia in addition to standard oncological therapy (radiation therapy, chemotherapy, radiochemotherapy) will be included in this registry protocol.
478 studies on the registry are indexed under Hyperthermia; 92 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 88 observational studies indexed under Hyperthermia.
Browse Hyperthermia studies →This is the only study on the registry with Pirus Ghadjar as lead sponsor.
Counted across the registry records on this site, refreshed daily.
It is planned to include the first 1.000 patients in this prospective database. Because of the characters in the database is a certain gender distribution not laid down . Confinement are capable of all patients in the Charité , which has a hyperthermia treatment , regardless of age or gender
Exclusion Criteria:
Hyperthermia simultaneous with Radiotherapy alone, Hyperthermia simultaneous with Chemotherapy alone, Hyperthermia simultaneous with Radiochemotherapy alone
Other: Hyperthermie Register
* die Höhe der Temperatur im Zielgebiet (42,5 bis 43 °C), * die Dauer der Anwendung und * die simultane Therapie mit Chemo- und/oder Strahlentherapie
Effectivity
To determine the effectiveness of hyperthermia treatment, patients are tracked in terms of overall survival , progression-free survival and disease-free survival
Time frame: Through the study completion, up to 10 years
Toxicity
Toxicity assessment based on Common Toxicity Criteria Scoring
Time frame: Through the study completion, up to 10 years
Plan to share: Yes
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.